Arovella Therapeutics Ltd (ASX:ALA), a leading biotechnology firm specialising in invariant Natural Killer T (iNKT) cell therapy, has announced the appointment of Tim Luscombe as its new chief financial officer (CFO) and company secretary, effective from December 1, 2023.
Tim Luscombe, with more than a decade of experience in finance and commercial sectors, will be taking over from Phillip Hains, who has held these positions since July 2020.
Luscombe's expertise stems from his role as a director at Bio101 Financial Advisory, a firm dedicated to providing financial, taxation, and secretarial services to the healthcare sector. He holds a Bachelor of Commerce degree from the University of Melbourne and a Certificate in Governance Practice from the Governance Institute of Australia.
A qualified chartered accountant, Luscombe currently holds similar roles in several other healthcare organisations, both listed and private.
The transition follows Phillip Hains’ resignation, with the board extending its gratitude for his significant contributions to Arovella over the last three and a half years.
In his new role at Arovella, Luscombe will be instrumental in managing the company's communications with the ASX, particularly concerning Listing Rule matters as outlined in ASX Listing Rule 12.6.